Questions remain about the human papillomavirus vaccine.
Printz
Carrie
C
D002487:Centers for Disease Control and Prevention, U.S.; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007115:Immunization Schedule; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control*
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18